News | December 20, 2022
Ipca acquires further 6.53% of equity share of Trophic Wellness
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
We must try to make the health care system more accessible for people with disabilities
A primary investment of Rs 194.4 crore has been made
Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
Acquisition includes 43.3%–48.2% equity stake and open offer to public shareholders; deal financed through term loan and equity instruments
Subscribe To Our Newsletter & Stay Updated
